Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT01833611
- Locations
- 🇨🇳
Chia-Yi Christian Hospital, Chia-Yi, Taiwan
🇨🇳Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan
🇨🇳Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 621
- Registration Number
- NCT01720238
- Locations
- 🇨🇳
Beijing 302 Hospital, Beijing, Beijing, China
🇨🇳Beijing Ditan Hospital, Beijing, Beijing, China
🇨🇳PeKing University People's Hopital, Beijing, Beijing, China
Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- New Discovery LLC
- Target Recruit Count
- 48
- Registration Number
- NCT01715987
- Locations
- 🇺🇸
New Discovery LLC, New York, New York, United States
🇺🇸Asian Pacific Liver Center at St. Vincent Medical Center, Los Angeles, California, United States
Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2016-11-09
- Lead Sponsor
- Korea University
- Target Recruit Count
- 60
- Registration Number
- NCT01711567
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT01694264
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷Inha University Hospital, Incheon, Korea, Republic of
🇰🇷Chonnam National University Hospital, Gwangju, Korea, Republic of
Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 88
- Registration Number
- NCT01639092
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 102
- Registration Number
- NCT01639066
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT01627223
- Locations
- 🇨🇳
ChengChing Hospital, Taichung, Taiwan
🇨🇳Chung Shan Medical University Hospital, Taichung, Taiwan
🇨🇳National Taiwan University Hospital Yu-Lin Branch, YuLin, Taiwan
Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT01599130
- Locations
- 🇨🇳
The Third Affliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 98
- Registration Number
- NCT01595685
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.